Phesgo and Tecentriq Performance and Approvals
Q1 2023: Strong underlying sales excluding COVID-19 decline
Group sales -3% driven by expected decline in COVID-19 testing
·
Strong Pharma performance (+9%) driven by ongoing portfolio rejuvenation
.
Good Diagnostics base business growth (+4%)
•
COVID-19 sales decline in line with FY 2023 expectations
Roche
Growth supported by key products and strong launches
•
•
•
Pharma key products Vabysmo, Ocrevus, Hemlibra, Evrysdi, Tecentriq, Perjeta, Phesgo and Polivy continuing to grow strongly
Key Pharma approvals: Polivy in 1L DLBCL in the US, Hemlibra in moderate hem A in the EU, Columvi (glofitamab) in 3L+ DLBCL in Canada
Diagnostics: launches of new tests in oncology, navify Algorithm Suite and navify Marketplace
Update on pipeline newsflow in 2023
•
•
Positive Phase III results for Tecentriq + Avastin in adjuvant HCC and crovalimab in PNH achieved
Pharma: 14 upcoming late-stage read-outs incl. 2 NMEs (tiragolumab, SRP-9001) and important line extensions for Ocrevus, Tecentriq,
Venclexta, TNKase, Alecensa and Lunsumio
•
Diagnostics: CCM Vertical, LightCycler Pro, Anti-HEV IgG/IgM, HBeAg Quant, and IL-6 Neonatal sepsis
Growth rates at CER (Constant exchange Rates); DLBCL= diffuse large B-Cell lymphoma; NME=new molecular entity; HCC-hepatocellular carcinoma; PNH=paroxysmal nocturnal hemoglobinuria
6View entire presentation